MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1.

BACKGROUND & AIMS Recent studies have emphasized causative links between microRNA (miRNA) deregulations and cancer development. In hepatocellular carcinoma (HCC), information on differentially expressed miRNA remained largely undefined. METHODS Array-based miRNA profiling was performed on HCC cells that were derived from chronic carriers of hepatitis B virus (HBV) and hepatitis C virus (HCV), and nonviral-associated patients. Specific microRNA (miR)-223 and miR-222 deregulations were verified in an independent series of tumors. The functional effect of miR-223 was examined further. An integrative analysis of messenger RNA (mRNA) array with in silico predictions defined potential downstream targets of miR-223. A luciferase reporter assay was conducted to confirm target association. RESULTS Distinct up-regulations of miR-222, miR-221, and miR-31, and down-regulations of miR-223, miR-126, and miR-122a were identified. Further investigations suggested the highly deregulated miR-223 and miR-222 could unequivocally distinguish HCC from adjacent nontumoral liver, irrespective of viral associations (P <or= .0002). Re-expression of miR-223 in HBV, HCV, and non-HBV non-HCV-related HCC cell lines revealed a consistent inhibitory effect on cell viability (P < .01). Integrative analysis further implicated Stathmin 1 (STMN1) as a downstream target of miR-223. A strong inverse relationship between STMN1 mRNA and miR-223 expressions was shown (P = .006). A substantial reduction in STMN1 protein was further demonstrated upon restoration of miR-223 expression in HCC cell lines. We further showed that miR-223 readily could suppress the luciferase activity in reporter construct containing the STMN1 3' untranslated region (P = .02). CONCLUSIONS Our study revealed specific miRNA differential expressions in HCC and underscores the potential importance of miR-223 down-regulations in the development of HCC.

[1]  P. Schirmacher,et al.  Protumorigenic overexpression of stathmin/Op18 by gain‐of‐function mutation in p53 in human hepatocarcinogenesis , 2007, Hepatology.

[2]  K. Hruska,et al.  MicroRNA‐223 is a key factor in osteoclast differentiation , 2007, Journal of cellular biochemistry.

[3]  L. Fazli,et al.  Increased expression and differential phosphorylation of stathmin may promote prostate cancer progression , 2007, The Prostate.

[4]  C. Croce,et al.  Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. , 2007, Cancer research.

[5]  Yoko Fukuda,et al.  An Evolutionarily Conserved Mechanism for MicroRNA-223 Expression Revealed by MicroRNA Gene Profiling , 2007, Cell.

[6]  W. Hait,et al.  Reversal of Stathmin-Mediated Resistance to Paclitaxel and Vinblastine in Human Breast Carcinoma Cells , 2007, Molecular Pharmacology.

[7]  M. Ringnér,et al.  Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity , 2007, Proceedings of the National Academy of Sciences.

[8]  Michael T. McManus,et al.  Dysregulation of Cardiogenesis, Cardiac Conduction, and Cell Cycle in Mice Lacking miRNA-1-2 , 2007, Cell.

[9]  S. Franceschi,et al.  Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review , 2007, British Journal of Cancer.

[10]  George A Calin,et al.  Identification of differentially expressed microRNAs by microarray: A possible role for microRNA genes in pituitary adenomas , 2007, Journal of cellular physiology.

[11]  Thomas D. Schmittgen,et al.  Expression profiling identifies microRNA signature in pancreatic cancer , 2006, International journal of cancer.

[12]  Z. Goodman.  Neoplasms of the liver , 2007, Modern Pathology.

[13]  C. Croce,et al.  Cyclin G 1 Is a Target of miR-122 a , a MicroRNA Frequently Down-regulated in Human Hepatocellular Carcinoma , 2007 .

[14]  Laura Mariani,et al.  MicroRNAs modulate the angiogenic properties of HUVECs. , 2006, Blood.

[15]  M. Rattray,et al.  A tumor progression model for hepatocellular carcinoma: bioinformatic analysis of genomic data. , 2006, Gastroenterology.

[16]  Oliver Hobert,et al.  Perfect seed pairing is not a generally reliable predictor for miRNA-target interactions , 2006, Nature Structural &Molecular Biology.

[17]  Y. Jeng,et al.  Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma , 2006, The Journal of pathology.

[18]  X. Agirre,et al.  Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues , 2006, Molecular Cancer.

[19]  Kristoffer Brännström,et al.  Aneugenic activity of Op18/stathmin is potentiated by the somatic Q18-->e mutation in leukemic cells. , 2006, Molecular biology of the cell.

[20]  C. Benz,et al.  Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies , 2006, Molecular Cancer.

[21]  Tushar Patel,et al.  Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. , 2006, Gastroenterology.

[22]  N. Rajewsky.  microRNA target predictions in animals , 2006, Nature Genetics.

[23]  T. Okanoue,et al.  Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues , 2006, Oncogene.

[24]  R. Stephens,et al.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. , 2006, Cancer cell.

[25]  N. Rajewsky,et al.  Cell-type-specific signatures of microRNAs on target mRNA expression. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[26]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Bruix,et al.  Treatment of hepatocellular carcinoma , 1997, Critical reviews in oncology/hematology.

[28]  C. Croce,et al.  The role of microRNA genes in papillary thyroid carcinoma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Alessandro Fatica,et al.  A Minicircuitry Comprised of MicroRNA-223 and Transcription Factors NFI-A and C/EBPα Regulates Human Granulopoiesis , 2005, Cell.

[30]  Muller Fabbri,et al.  A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. , 2005, The New England journal of medicine.

[31]  C. Croce,et al.  miR-15 and miR-16 induce apoptosis by targeting BCL2. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[32]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[33]  K. Kosik,et al.  MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. , 2005, Cancer research.

[34]  Yong Zhao,et al.  Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis , 2005, Nature.

[35]  J. Squire,et al.  Transcriptional profiling on chromosome 19p indicated frequent downregulation of ACP5 expression in hepatocellular carcinoma , 2005, International journal of cancer.

[36]  F. X. Bosch,et al.  Epidemiology of hepatocellular carcinoma. , 2005, Clinics in liver disease.

[37]  J. Squire,et al.  Transcriptional profiling identifies gene expression changes associated with IFN-alpha tolerance in hepatitis C-related hepatocellular carcinoma cells. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  C. Burge,et al.  Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.

[39]  G. Atweh,et al.  The role of stathmin in the regulation of the cell cycle , 2004, Journal of cellular biochemistry.

[40]  C. Croce,et al.  MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[41]  S. Fan,et al.  Clinicopathologic significance of genetic alterations in hepatocellular carcinoma. , 2003, Cancer genetics and cytogenetics.

[42]  Michael Z Michael,et al.  Reduced accumulation of specific microRNAs in colorectal neoplasia. , 2003, Molecular cancer research : MCR.

[43]  V. Ambros,et al.  MicroRNA Pathways in Flies and Worms Growth, Death, Fat, Stress, and Timing , 2003, Cell.

[44]  J. Squire,et al.  Chromosomal localization of DNA amplifications in neuroblastoma tumors using cDNA microarray comparative genomic hybridization. , 2003, Neoplasia.

[45]  W. Lau,et al.  Consistent chromosome 10 rearrangements in four newly established human hepatocellular carcinoma cell lines , 2002, Genes, chromosomes & cancer.

[46]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[47]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[48]  S. Hanash,et al.  Oncoprotein 18 levels and phosphorylation mediate megakaryocyte polyploidization in human erythroleukemia cells , 2001, Proteomics.

[49]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[50]  K. Yeo,et al.  Characterization of cell lines established from human hepatocellular carcinoma , 1995, International journal of cancer.

[51]  G. Landberg,et al.  Quantitative analysis of the expression and regulation of an activation-regulated phosphoprotein (oncoprotein 18) in normal and neoplastic cells. , 1993, Leukemia.

[52]  H. Koyama,et al.  Influence of coexisting cirrhosis on long-term prognosis after surgery in patients with hepatocellular carcinoma. , 1992, Surgery.

[53]  J. Strahler,et al.  Involvement of OP18 in cell proliferation. , 1991, Biochemical and biophysical research communications.

[54]  F. Miglio,et al.  [Epidemiology of hepatocellular carcinoma]. , 1991, Minerva gastroenterologica e dietologica.

[55]  N. Okazaki,et al.  Prognosis of Primary Hepatocellular Carcinoma , 1984, Hepatology.